Safety and efficacy of ledipasvir/sofosbuvir on hepatitis C eradication in hepatitis C virus/human immunodeficiency virus co-infected patients
Xiaoping He, George Everett, Khalid Abusaada, Vincent Hsu, the Internal Medicine Residency Program of Florida Hospital, Orlando, FL 32804, United States
Lynne Hopkins, Willie M Carter, Cynthia SchroppDyce, Sunshine Care Center, Florida Department of Health in Orange County, Orlando, FL 32804, United States
Author contributions: He X contributed to protocol design and development, data collection and analysis, and writing of the ﬁrst draft of the manuscript; Hopkins L contributed to protocol design and development, and writing of the manuscript; Carter WM and SchroppDyce C contributed to protocol development; Everett G, Abusaada K and Hsu V contributed to critical manuscript revision.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Sunshine Care Center, Florida Department of Health in Orange County.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment.
Conflict-of-interest statement: The authors have no financial relationships to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Xiaoping He, MD, PhD, the Internal Medicine Residency Program of Florida Hospital, 2501 North Orange Ave, Suite 235, Orlando, FL 32804, United States. email@example.com
Telephone: +1-407-3037270 Fax: +1-407-3032553
Received: April 6, 2017
Peer-review started: April 10, 2017
First decision: May 19, 2017
Revised: July 14, 2017
Accepted: September 3, 2017
Article in press: September 4, 2017
Published online: October 28, 2017